Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
ISIN : US60770K1079
Total Employee Number:
4,700Compare
Compare
Traded in other countries / regions
MRNA.USA0A45.UKM1RN34.Brazil0QF.Germany1MRNA.ItalyMRNA.AustriaMRNA.MexicoMRNA.Peru0QF.BulgariaMRNA_KZ.KazakhstanMRNA.Switzerland Index Membership
S&P 500Russell 1000Russell 3000NASDAQ 100 IPO Date
2018-12-07Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.01 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.45 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 4.28 | |||||
Beneish M-Score | -3.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -52.2 | |||||
3-Year Book Growth Rate | -23.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.29 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.98 | |||||
9-Day RSI | 48.46 | |||||
14-Day RSI | 53.7 | |||||
3-1 Month Momentum % | -5.55 | |||||
6-1 Month Momentum % | 22.99 | |||||
12-1 Month Momentum % | 51.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.41 | |||||
Quick Ratio | 2.35 | |||||
Cash Ratio | 2.17 | |||||
Days Inventory | 42.08 | |||||
Days Sales Outstanding | 46.87 | |||||
Days Payable | 48.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -0.15 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 21.37 | |||||
Operating Margin % | -154.81 | |||||
Net Margin % | -144.92 | |||||
EBITDA Margin % | -130.54 | |||||
FCF Margin % | -72.73 | |||||
OCF Margin % | -66.52 | |||||
ROE % | -35.61 | |||||
ROA % | -26.32 | |||||
ROIC % | -50.07 | |||||
3-Year ROIIC % | 143.1 | |||||
ROC (Joel Greenblatt) % | -107.27 | |||||
ROCE % | -30.25 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 53.95 | |||||
PS Ratio | 11.98 | |||||
PB Ratio | 3.61 | |||||
Price-to-Tangible-Book | 3.69 | |||||
EV-to-EBIT | -7.34 | |||||
EV-to-Forward-EBIT | -6.13 | |||||
EV-to-EBITDA | -7.94 | |||||
EV-to-Forward-EBITDA | -6.53 | |||||
EV-to-Revenue | 10.37 | |||||
EV-to-Forward-Revenue | 11.13 | |||||
EV-to-FCF | -14.26 | |||||
Price-to-GF-Value | 2.95 | |||||
Price-to-Projected-FCF | 0.96 | |||||
| Price-to-Net-Current-Asset-Value | 15.83 | |||||
| Price-to-Net-Cash | 23.75 | |||||
Earnings Yield (Greenblatt) % | -13.62 | |||||
FCF Yield % | -5.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moderna Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,204 | ||
| EPS (TTM) ($) | -8.15 | ||
| Beta | 0.1279 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.1 | ||
| Volatility % | 73.11 | ||
| 14-Day RSI | 53.7 | ||
| 14-Day ATR ($) | 5.034296 | ||
| 20-Day SMA ($) | 67.38575 | ||
| 12-1 Month Momentum % | 51.84 | ||
| 52-Week Range ($) | 22.28 - 85.6 | ||
| Shares Outstanding (Mil) | 396.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moderna Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moderna Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 114 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:00 | In 17 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 16 days | ||
| Moderna Science Day | 2026-06-25 09:00 | 60.42 (-1.23%) | ||
| Guidance call for 2026 | 2026-06-09 15:20 | 47.60 (-1.29%) | ||
| Bernstein\'s 42nd Annual Strategic Decisions Conference | 2026-05-28 10:00 | 47.61 (+1.25%) | ||
| Guidance call for 2026 | 2026-05-19 10:00 | 48.11 (-3.74%) | ||
| Guidance call for 2026 | 2026-05-12 11:20 | 52.88 (-8.95%) | ||
| General meeting for 2026 | 2026-05-06 08:00 | 46.71 (-2.02%) |
Show
Entries
Moderna Inc Frequently Asked Questions
What is Moderna Inc(MRNA)'s stock price today?
The current price of MRNA is $67.44. The 52 week high of MRNA is $85.60 and 52 week low is $22.28.
When is next earnings date of Moderna Inc(MRNA)?
The next earnings date of Moderna Inc(MRNA) is 2026-07-31.
Does Moderna Inc(MRNA) pay dividends? If so, how much?
Moderna Inc(MRNA) does not pay dividend.
Guru Commentaries on NAS:MRNA
No articles.
Press Release
Articles on Moderna Inc
Headlines
See More- 1
Jul 13, 2026
U.S. advises against Congo travel after second American aid worker contracts Ebola
Seeking Alpha • 7:08am
Jul 10, 2026
Wall Street trades relatively muted at the end of the week
Seeking Alpha • 8:58am
Jul 09, 2026
Moderna wins EU deal to supply up to 24M doses of RSV vaccine
Seeking Alpha • 9:09am
RFK Jr. to create a list of injuries caused by COVID-19 shots
Seeking Alpha • 7:14am
Jul 08, 2026
Moderna appoints Michael McDonnell to board; shares retreat from 52-week high
Seeking Alpha • 2:45pm
Jul 01, 2026
Four stock-moving events to watch as FDA revives AdComs
Seeking Alpha • 12:51pm
Jun 30, 2026
RFK Jr. ends Emergency Use Authorizations for COVID-19 drugs
Seeking Alpha • 1:30pm
Jun 26, 2026
Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75?
Seeking Alpha • 12:42pm
Jun 22, 2026
Moderna snaps after six-session winning streak
Seeking Alpha • 1:05pm
Jun 18, 2026
Moderna gains unanimous FDA panel endorsement of flu vaccine
Seeking Alpha • 4:00pm
Jun 17, 2026
4 stocks to watch on Wednesday: MSFT, MRNA, MU, AMZN
Seeking Alpha • 7:49am
Moderna eyes German production sites amid BioNTech plant closures - report
Seeking Alpha • 2:19am
Jun 16, 2026
Moderna hits three-month high after FDA review for flu shot (update)
Seeking Alpha • 1:26pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers